Proteostasis Therapeutics (NASDAQ:PTI) is up 21% premarket after announcing results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19.
PTI-129 is a pre-clinical, oral small molecule
originally designed to treat protein misfolding disorders involving the
unfolded protein response (UPR).
In in vitro studies conducted at Calibr, the drug
discovery division of Scripps Research, PTI-129 demonstrated the
potential to reduce viral protein production in host cells by activating
the adaptive branches of the UPR pathway and reducing the levels of
misfolded proteins.
https://seekingalpha.com/news/3578955-proteostasis-therapeutics-ptiminus-129-potential-covidminus-19-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.